December 07, 2023
The Federal Circuit has backed a decision that a slew of generic-drug makers don't infringe two of H. Lundbeck's patents on antidepressant drug Trintellix, while also affirming a decision that Lupin Pharmaceuticals Inc. infringes another patent.
June 17, 2022
Lupin Pharmaceuticals Inc. is urging the Federal Circuit to reverse a decision that its abbreviated new drug application for a proposed generic infringes one of three patents covering Takeda's antidepressant drug Trintellix, saying the district court erred in construing a key claim term.
March 23, 2022
Takeda Pharmaceuticals has asked the Federal Circuit to undo a decision — made by a former federal judge who just took a seat on the appeals court — that a slew of generic-drug makers don't infringe two of its patents on antidepressant drug Trintellix.